Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 20222923.
- Also identified by DOI 10.1111/j.1365-2133.2010.09751.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Keratoacanthomas are squamous cell neoplasms known to be abundant in epidermal growth factor receptors (EGFRs). Erlotinib (Tarceva(®); Roche) is a low molecular weight oral quinazoline compound that binds to the intracellular EGFR tyrosine kinase domain and inhibits receptor phosphorylation and downstream signalling. We report a case of refractory, locally aggressive keratoacathoma centrifugum marginatum of the scalp having strong EGFR expression and demonstrating excellent response to erlotinib.
Medical subject headings
- Head and Neck Neoplasms
- Keratoacanthoma
- Protein Kinase Inhibitors
- Quinazolines
- Scalp
- Skin Neoplasms